Medicine
Axycis 50 mg/50 mL injection
Axycis 50 mg/50 mL injection is a prescription medicine containing Cisplatin for intravenous use, marketed by Avyxa Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not refrigerate. Store in original carton at 20°C to 25°C (68°F to 77°F)…
Key facts
- Active ingredient (INN)
- Cisplatin
- Brand
- Axycis
- Strength
- 50 mg/50 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 50 mL
- Marketing authorisation holder
- Avyxa Pharma
- Manufacturer
- Avyxa Pharma
- Origin register
- US FDA, United States
- Storage
- Do not refrigerate. Store in original carton at 20°C to 25°C (68°F to 77°F), excursions permitted from 15°C to 30°C (59°F to 86°F). Retain in original carton to protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XA01 Cisplatin
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 29 October 2026
- Identifiers
- DailyMed set ID 93edf309-993c-48ec-be90-27d89c86b62bNDC 83831-158Application NDA220748
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, multi-dose in 1 carton / 50 mL in 1 vial, multi-dose | 83831-158-01 | AVYXA Pharma | 29 October 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 19 December 1978 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Cisplatin 50 mg/50 mL injection.
Other strengths and forms of Cisplatin
Clinical summary
Cisplatin is a platinum-based drug indicated for the treatment of advanced testicular cancer, among other approved uses. It is available as injection and powder for injection for intravenous use. MedsAcross supplies Cisplatin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CisplatinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Cisplatin prescribing information (WG Critical Care) · U.S. National Library of Medicine, DailyMed
Need Axycis 50 mg/50 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.